Form 4: Natera Executive Chairman Sells $21M in Stock

Executive Chairman Matthew Rabinowitz sold 100,000 shares of Natera, Inc. common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Executive Chairman Matthew Rabinowitz sold a total of 100,000 shares of Natera, Inc. (NTRA) common stock over two trading days.
• The transactions occurred on June 12, 2026, and June 15, 2026, with 50,000 shares sold on each day.
• Sales were executed in multiple tranches at weighted average prices ranging from $209.49 to $219.35 per share.
• The total gross proceeds from these sales are approximately $21.3 million.
• Following these transactions, Rabinowitz continues to hold 2,277,843 shares directly and 5,000 shares indirectly through his spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while the dollar amount is large, the sale was pre-planned and the Executive Chairman retains the vast majority of his stake.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan adopted on March 13, 2026, which helps mitigate concerns regarding insider trading based on non-public information.
• The reporting person maintains a very substantial equity position in the company, holding over 2.27 million shares even after this $21 million divestment.
• The shares were sold at relatively high price points, with some tranches exceeding $219 per share.

Negatives

• A $21.3 million divestment by the Executive Chairman represents a significant liquidation of equity in a short period.
• Large-scale insider selling can sometimes be perceived by the market as a signal that leadership believes the stock is reaching a valuation ceiling.

Risks

• Potential for short-term downward pressure on the stock price due to the high volume of shares being sold in the open market.
• Market sentiment risk if investors interpret the sale as a lack of confidence in near-term upside, despite the use of a 10b5-1 plan.

Future Outlook

The use of a Rule 10b5-1 plan suggests that the reporting person may have additional scheduled sales in the future as part of a structured diversification strategy.

Management Comments

• The reporting person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes.

Industry Context

StockSavvy.ai notes that in the high-growth diagnostics and genetic testing sector, it is common for founders and long-tenured executives to utilize 10b5-1 plans for liquidity, especially after periods of strong stock performance.

Comparison to Industry Standards

• Natera's executive ownership remains high compared to peers like Guardant Health, where executive divestments have occasionally represented larger percentages of total holdings.
• The use of 10b5-1 plans is the standard best practice for S&P 500 and Russell 1000 executives to manage regulatory and reputational risk during stock sales.

Related Party Transactions

• The reporting person is the Executive Chairman and a Director, making this a related party transaction involving the sale of company equity.

Stakeholder Impact

• Shareholders may experience minor volatility due to the increased supply of shares in the market.
• The transaction provides liquidity to the Executive Chairman but does not dilute existing shareholders as these were secondary market sales.

Next Steps

• Monitor for additional Form 4 filings to see if the 10b5-1 plan includes further tranches of sales in the coming months.

Key Dates

Recommendation

The insider selling is significant in value but appears to be routine portfolio diversification rather than a lack of confidence in the company's fundamentals, especially given the remaining multi-million share stake.

Keywords

Natera, NTRA, Insider Selling, Matthew Rabinowitz, Form 4, 10b5-1 Plan, Executive Chairman, Genetic Testing, Diagnostics